DBV Technologies | DBVT - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -852K 7.26M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
DBV Technologies USD -33.16M 8.6M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Galectin Therapeutics USD -12.37M 880K 2024-06
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
United Therapeutics USD 444M 6M 2025-12